Compounded GLP-1 Medications - Defective Drug Site

FDA Regulation, Corporate Lawsuits Against Compounders, Safety Risks, and State Enforcement Actions

The explosive growth of GLP-1 medications such as Ozempic, Wegovy, Mounjaro, and Zepbound created demand that the pharmaceutical supply chain was not immediately equipped to meet. As shortages spread across the country, a parallel industry took shape almost overnight: compounding pharmacies, outsourcing facilities, telehealth platforms, and wellness clinics began producing and marketing their own versions of semaglutide and tirzepatide, typically at lower prices and with fewer barriers to access than the branded products.

What followed has become one of the most contentious pharmaceutical and regulatory conflicts in recent memory. The compounded GLP-1 market attracted scrutiny from the FDA, aggressive litigation from Novo Nordisk and Eli Lilly, enforcement actions from state pharmacy boards, and a growing body of reports linking compounded products to patient injuries. The controversy touches on drug regulation, patient safety, corporate intellectual property, and the expanding role of telehealth in prescription drug distribution. This article explains how compounded GLP-1 medications work, the legal framework that governs them, the enforcement actions that followed their proliferation, and the safety concerns that have emerged from real-world use.

What Are Compounded GLP-1 Medications?

Compounded medications are drugs prepared by pharmacies or outsourcing facilities rather than manufactured through the FDA’s standard drug approval process. In the context of GLP-1 therapy, compounded products entered the market as alternatives to branded medications during periods of shortage and, in some cases, were marketed as lower-cost substitutes even when branded supply was available. Compounded GLP-1 products have taken a variety of forms, including:

Compounded Ozempic (semaglutide) and compounded Mounjaro (tirzepatide) in injectable formulations
Custom dosages not available in FDA-approved products
Oral or sublingual formulations, which have no FDA-approved equivalent
Combinations of GLP-1 compounds with vitamins, amino acids, or other additives

The critical regulatory distinction is that compounded GLP-1 drugs are generally not FDA-approved. The agency has been explicit that compounded drugs do not undergo its standard review for safety, effectiveness, manufacturing consistency, or quality control. (U.S. Food and Drug Administration)

Why Compounded GLP-1 Drugs Became So Popular

The rise of compounded GLP-1 products was not driven by a single factor but by a confluence of market conditions, policy gaps, and patient need that created the conditions for rapid industry growth.

A. National Drug Shortages

The FDA placed semaglutide and tirzepatide on the national drug shortage list as patient demand far outpaced available supply. Under federal law, drug shortages can temporarily permit certain compounding activities that would otherwise be restricted — a legal opening that compounders moved quickly to exploit. (U.S. Food and Drug Administration)

B. Cost Barriers

FDA-approved GLP-1 medications carry list prices that frequently reach hundreds or thousands of dollars per month. For patients without insurance coverage or with inadequate coverage, branded products were financially out of reach. Compounded alternatives were consistently marketed as substantially cheaper options, with some telehealth platforms advertising compounded semaglutide at a fraction of the cost of Ozempic or Wegovy.

C. Telehealth Expansion

The post-pandemic growth of telehealth infrastructure gave compounders a powerful distribution channel. A new category of direct-to-consumer weight-loss platforms emerged, offering online consultations, subscription programs, and home delivery of compounded GLP-1 injections — often with minimal clinical oversight and aggressive digital marketing.

D. Limited Insurance Coverage

A significant proportion of patients who might otherwise have accessed FDA-approved products were blocked from doing so by insurance formulary restrictions. Many commercial health plans and most Medicaid programs did not cover GLP-1 medications for weight loss unless the patient also had a qualifying condition such as Type 2 diabetes. Compounded products filled that access gap for patients who were medically appropriate candidates for GLP-1 therapy but could not obtain or afford branded medications.

FDA Regulation of Compounding Pharmacies

Compounding pharmacies and outsourcing facilities operate under a distinct legal framework from traditional pharmaceutical manufacturers, governed primarily by two sections of the Federal Food, Drug, and Cosmetic Act. Understanding this framework is essential for evaluating the legal status of compounded GLP-1 products and the basis for FDA enforcement actions.

Section 503A: Traditional Compounding Pharmacies

A 503A pharmacy compounds medications for individual patients pursuant to a valid prescription. These pharmacies are primarily regulated by state pharmacy boards rather than the FDA, and they are exempt from certain federal manufacturing requirements provided they operate within defined legal boundaries — including the requirement that they not produce copies of commercially available drugs except under specific circumstances such as a documented shortage. (U.S. Food and Drug Administration)

Section 503B: Outsourcing Facilities

A 503B outsourcing facility is permitted to compound larger batch quantities and distribute products to healthcare facilities without patient-specific prescriptions. These facilities are subject to more rigorous FDA oversight than 503A pharmacies, including inspection requirements and adherence to current good manufacturing practice (cGMP) standards. However, 503B products still do not undergo full FDA approval and are not reviewed for safety and effectiveness in the same manner as commercially approved drugs. (U.S. Food and Drug Administration)

When Is Compounding Legally Permitted?

The legal basis for compounding a particular drug is fact-specific and has been at the center of significant litigation. Compounding may be lawful under federal law in two principal circumstances. First, when a drug is listed on the FDA shortage list — which was the primary legal justification for widespread GLP-1 compounding during the shortage period. Second, when a patient has a documented medical need that cannot be met by an available FDA-approved product, such as an allergy to a specific inactive ingredient or a requirement for a specialized formulation or dosage form that does not exist in the commercial market.

FDA Crackdown on Compounded GLP-1 Drugs

As supply conditions for branded semaglutide and tirzepatide products stabilized, the FDA began systematically tightening the legal justification for continued compounding. The agency’s enforcement posture shifted materially in 2025 and into 2026, with a series of formal actions directed at the compounded GLP-1 market.

FDA Statements and Warnings

The FDA issued repeated public warnings emphasizing that compounded GLP-1 drugs are not FDA-approved, may present quality and safety risks that approved products do not, and are not interchangeable with branded medications. The agency also made clear that companies cannot legally market compounded products as “generic Ozempic,” as clinically equivalent alternatives to FDA-approved drugs, or as products supported by the same clinical evidence as branded GLP-1 medications. (U.S. Food and Drug Administration)

The Semaglutide Salt Controversy

A significant regulatory flashpoint involved compounders who used semaglutide sodium or semaglutide acetate — salt forms of the molecule — as the active ingredient in their products. The FDA took the position that these salt forms differ chemically from the active ingredient used in FDA-approved semaglutide products and had not been demonstrated to be safe or effective. The use of these unapproved variants became a specific basis for enforcement action. (U.S. Food and Drug Administration)

FDA Proposal to Restrict Bulk GLP-1 Compounding

In April 2026, the FDA announced a proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list — the list of bulk drug substances that outsourcing facilities are permitted to use in compounding. The agency determined there was no demonstrated clinical need for outsourcing facilities to compound these drugs from bulk substances, given the availability of FDA-approved alternatives. If finalized, this proposal would represent a near-complete closure of the legal pathway that had sustained large-scale GLP-1 compounding operations. (U.S. Food and Drug Administration)

FDA Warning Letters and Enforcement Actions

The FDA’s enforcement activity extended to individual companies through the issuance of formal warning letters. The agency targeted online sellers, telehealth platforms, compounding pharmacies, and wellness clinics for a range of violations including misleading advertising, unlawful compounding practices, and improper marketing claims. Reports indicate the FDA issued more than 50 warning letters related to GLP-1 compounding and marketing practices, with the volume of enforcement activity accelerating significantly in 2025.

See example: FDA Warning Letter — GLP-1 Solution (September 2025)

Corporate Lawsuits Against Compounders

Alongside the federal regulatory campaign, Novo Nordisk and Eli Lilly pursued their own aggressive legal strategies against the compounded GLP-1 market. These civil actions have targeted compounders, telehealth operators, and pharmacies on multiple legal theories including patent infringement, trademark violations, false advertising, and patient safety concerns.

Eli Lilly Lawsuits

Eli Lilly filed lawsuits against multiple compounding operations, with Reuters reporting actions against Strive Pharmacy and Empower Clinic Services for allegedly selling unapproved tirzepatide products and making misleading claims about their safety and efficacy. (Reuters)

Lilly’s complaints alleged that some compounded products falsely implied superior safety profiles compared to Zepbound, contained added ingredients such as vitamin B12 or glycine that were not present in the approved formulation, and improperly leveraged Lilly’s own clinical trial data to suggest efficacy that had not been independently established for the compounded versions. (Reuters)

Novo Nordisk Litigation

Novo Nordisk similarly pursued a broad litigation campaign against telehealth companies, online marketers, and pharmacies distributing compounded semaglutide products. The company’s complaints typically alleged unlawful copying of semaglutide formulations, false advertising, trademark infringement, and endangerment of patient safety through the distribution of products that had not undergone regulatory scrutiny. (Washington Post)

Novo Nordisk also pursued a parallel enforcement strategy involving cease-and-desist letters, legal demands, and targeted injunction proceedings against compounders and telehealth operators. By early 2026, the company had filed more than 110 federal lawsuits across 32 states and obtained permanent injunctions against a significant number of defendants.

Telehealth Companies Under Scrutiny

The telehealth sector became a focal point of both FDA and corporate enforcement efforts. Companies offering subscription-based weight-loss programs built around compounded GLP-1 products were criticized for aggressive direct-to-consumer advertising, the marketing of compounded oral GLP-1 formulations with no FDA-approved equivalent, and in some cases for making clinical claims that exceeded what the evidence supported. (Washington Post)

Safety Concerns With Compounded GLP-1 Drugs

Beyond the legal and regulatory dimensions of the compounded GLP-1 controversy, a substantial body of evidence has accumulated raising genuine patient safety concerns. These concerns are not theoretical — they are grounded in adverse event reports, FDA inspection findings, and documented product deficiencies that distinguish compounded products from the FDA-approved medications they were designed to replicate.

Reported Side Effects and Injuries

Patients using compounded GLP-1 products have reported a range of adverse outcomes, with the FDA acknowledging that it received hundreds of adverse event reports linked to compounded semaglutide and tirzepatide products. The reported effects span a spectrum from common GLP-1-class reactions to more serious complications potentially attributable to quality failures in the compounded product itself. Reported adverse events have included:

Severe nausea, vomiting, and diarrhea
Abdominal pain and gastrointestinal distress
Significant dehydration requiring medical attention
Injection site reactions and local complications
Dosing errors resulting in overdose or inadequate therapeutic effect

Dosing Errors

One of the most practically significant safety distinctions between compounded and FDA-approved GLP-1 products is the delivery mechanism. FDA-approved injector pens are designed with fixed, pre-loaded doses and intuitive administration systems that minimize the risk of user error. Compounded products, by contrast, are frequently supplied in multidose vials that require patients to manually draw up and measure their own doses using syringes. The concentration of the compounded product may differ from what the patient expects, instructions may be ambiguous, and the margin for error is meaningfully higher. The consequences of dosing errors can include:

Accidental overdose leading to severe gastrointestinal toxicity or hypoglycemia
Underdosing resulting in inadequate glycemic control or weight management
Hospitalization in cases of significant overdose or adverse reaction

Contamination and Sterility Risks

Injectable medications carry inherent sterility requirements that are rigorously enforced for FDA-approved products. Compounding facilities, particularly smaller 503A pharmacies operating without the infrastructure of a major manufacturer, may not consistently meet those standards. FDA inspections have identified manufacturing deficiencies and sterility failures at compounding facilities producing GLP-1 products, and at least one documented recall was issued due to sterility concerns in a compounded semaglutide and tirzepatide product line. (MedShadow Foundation)

Counterfeit and Illegally Marketed Products

Separate from the compounded GLP-1 market — which, however problematic, operates through licensed pharmacy channels — the FDA has also raised alarms about outright counterfeit GLP-1 products circulating through unregulated online channels. These products may contain incorrect or entirely absent active ingredients, dangerous contaminants, or wildly inconsistent dosages. The risk profile of these products is categorically different from and more severe than that of regulated but unapproved compounded products. (Drug Information Group, University of Illinois Chicago)

State Regulatory Actions Against Compounders

Federal enforcement has been accompanied by a parallel wave of state-level regulatory activity. State pharmacy boards, which have primary licensing and disciplinary authority over 503A compounding pharmacies, have increasingly directed resources toward GLP-1 compounding practices. The range of enforcement tools available to state regulators includes:

A. Pharmacy Board Investigations

State boards have opened investigations into pharmacies alleged to be engaged in unlawful compounding, improper dispensing practices, and recordkeeping violations related to GLP-1 products. These investigations can be triggered by consumer complaints, adverse event reports, or referrals from the FDA and other regulatory bodies.

B. License Discipline

The ultimate enforcement lever available to a state pharmacy board is the ability to discipline a pharmacy’s license. In cases of serious or repeated violations, consequences can escalate from monetary fines and formal reprimands through probationary conditions, suspension, and permanent revocation of the pharmacy’s license to operate.

C. Consumer Protection Actions

Several state attorneys general and consumer protection offices have also taken action against compounders and telehealth companies for deceptive advertising practices, including false claims of FDA equivalence, misleading comparisons to branded products, and pricing representations that obscured the unapproved nature of the products being sold.

Legal Gray Areas and Ongoing Court Battles

Despite the intensification of enforcement, the legal boundaries governing compounded GLP-1 products remain genuinely contested. The shortage-based legal exceptions that initially justified widespread compounding created a regulatory gray zone that FDA policy changes alone cannot fully resolve, and multiple federal courts are actively wrestling with the scope of the FDA’s authority in this space. (Courthouse News)

Litigation and appeals are ongoing on several fronts, including challenges to the FDA’s determination that the shortage has ended, disputes over the scope of lawful patient-specific compounding after shortage status is lifted, and legal challenges by compounding industry groups to the FDA’s proposed restrictions on bulk compounding. The outcomes of these proceedings will determine whether any meaningful portion of the compounded GLP-1 market survives the current enforcement environment.

Why the Distinction Between Compounded and FDA-Approved Products Matters

The regulatory distinction between FDA-approved GLP-1 medications and compounded alternatives has concrete clinical and legal consequences. FDA-approved drugs have undergone comprehensive clinical testing demonstrating safety and efficacy in the populations for which they are indicated. They are manufactured under current good manufacturing practice standards subject to ongoing FDA oversight. Their labeling has been reviewed and approved. Compounded products, as the FDA has stated repeatedly, receive none of those assurances. (U.S. Food and Drug Administration)

From a legal liability standpoint, this distinction creates meaningful differences in how injury claims are evaluated. Patients injured by FDA-approved GLP-1 products have a well-established framework for pursuing claims against Novo Nordisk or Eli Lilly through the existing MDL structure. Patients injured by compounded products face a different and in some respects more complicated legal landscape, with potential claims running against the compounding pharmacy, the prescribing telehealth provider, and potentially other parties in the distribution chain depending on the specific facts of their case.

Key Takeaways

The compounded GLP-1 controversy is one of the defining regulatory and legal stories of the current pharmaceutical landscape. For patients, clinicians, and legal professionals, the following points capture the essential picture:

Compounded GLP-1 medications expanded rapidly during shortages of FDA-approved products, driven by cost barriers, limited insurance coverage, and the growth of telehealth distribution
Compounded products are generally not FDA-approved and have not been independently evaluated for safety, effectiveness, or manufacturing consistency
The FDA has intensified enforcement as supply conditions have stabilized, including warning letters, proposed restrictions on bulk compounding, and public safety communications
Novo Nordisk and Eli Lilly have filed extensive civil litigation against compounders and telehealth companies on theories of patent infringement, trademark violations, and false advertising
Real-world adverse event reports have raised documented concerns about dosing errors, contamination, sterility failures, and injuries linked to compounded products
State pharmacy boards are increasingly investigating GLP-1 compounding practices and pursuing license discipline actions against non-compliant pharmacies
The legal landscape remains contested, with ongoing federal court proceedings addressing the scope of FDA authority and the future of compounding exceptions

As shortages resolve and federal enforcement continues to tighten, the compounded GLP-1 market faces significant legal and regulatory headwinds. Patients who have used compounded products and experienced adverse outcomes should consult with a qualified attorney to understand their options, as the applicable legal framework differs meaningfully from the litigation pathway available to patients injured by FDA-approved medications.

References